BHVN Stock Recent News
BHVN LATEST HEADLINES
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or “the Company”) (NYSE: BHVN) and certain of its officers.
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd.
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).
Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to review troriluzole to make an informed decision on whether or not it should be approved to treat SCA patients. Troriluzole's versatility across all SCA genotypes and lack of FDA-approved competing products make it a compelling investment opportunity.
NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline.
On a very good Friday for the stock market, Biohaven's (BHVN 6.33%) performance was exceptional. The clinical-stage biotech's share price inflated by over 6% that trading session thanks to regulatory news it delivered in the morning.
NEW YORK , Aug. 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"), of the important September 12, 2025 lead plaintiff deadline.